RNS Number : 7228Y MaxCyte, Inc. 05 January 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Grant of Options and PDMR Dealing ROCKVILLE, MD , 5 January 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases. ROCKVILLE, Md. and SINGAPORE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading,
RNS Number : 5279Y MaxCyte, Inc. 03 January 2024 MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline Lion TCR to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid
RNS Number : 3554Y MaxCyte, Inc. 02 January 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , January 2 , 2024 - MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 3253Y MaxCyte, Inc. 02 January 2024 MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director ROCKVILLE, MD , January 2, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
RNS Number : 1118Y MaxCyte, Inc. 29 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 29, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 4671W MaxCyte, Inc. 12 December 2023 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 MaxCyte Announces CEO
Doug Doerfler, President and CEO, to Retire Effective December 31, 2023; will continue to serve as an advisor to MaxCyte Maher Masoud, EVP, Head of Global Business Development and Chief Counsel, to Succeed Mr. Doerfler as President and CEO, Effective January 1, 2024 MaxCyte is reiterating
RNS Number : 0411W MaxCyte, Inc. 07 December 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , December 7, 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
